WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012051050) METHOD FOR TREATING CYSTIC FIBROSIS WITH INHALED DENUFOSOL
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/051050    International Application No.:    PCT/US2011/055121
Publication Date: 19.04.2012 International Filing Date: 06.10.2011
IPC:
A61K 31/7072 (2006.01)
Applicants: INSPIRE PHARMACEUTICALS, INC. [US/US]; 1 Merck Drive, P.O. Box 100 Whitehouse Station, New Jersey 08889-0100 (US) (For All Designated States Except US).
KRISHNAMOORTHY, Ramesh [IN/US]; (US) (For US Only).
EVANS, Carole M. [GB/US]; (US) (For US Only).
BURKE, Brian J. [US/US]; (US) (For US Only).
SCHABERG, Amy E. [US/US]; (US) (For US Only).
COADY, Thomas G. [US/US]; (US) (For US Only)
Inventors: KRISHNAMOORTHY, Ramesh; (US).
EVANS, Carole M.; (US).
BURKE, Brian J.; (US).
SCHABERG, Amy E.; (US).
COADY, Thomas G.; (US)
Agent: KUNG, Viola T.; Perkins Coie LLP P.O. Box 1208 Seattle, Washington 98111-1208 (US)
Priority Data:
61/392,363 12.10.2010 US
Title (EN) METHOD FOR TREATING CYSTIC FIBROSIS WITH INHALED DENUFOSOL
(FR) PROCÉDÉ DE TRAITEMENT DE LA FIBROSE KYSTIQUE AVEC DU DENUFOSOL INHALÉ
Abstract: front page image
(EN)The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, applying about 0.8-3 mL of a solution comprising about 18-65 mg/mL of denufosol into a medication reservoir of an nebulizer to achieve a target loading dose of denufosol of about 25-52 mg denufosol per dosing regimen, nebulizing the solution by passing through holes of an vibrating mesh device equipped with an oscillating membrane in the nebulizer, and delivering an inhaled respiratory dose of 20-33 mg to the lungs of the patient by inhalation within 3-9 minutes.
(FR)La présente invention concerne un procédé de traitement de la fibrose kystique. Le procédé comprend les étapes de : identification d'un patient souffrant de fibrose kystique, application d'environ 0,8-3 ml d'une solution comprenant environ 18-65 mg/ml de denufosol dans un réservoir de médicament d'un nébuliseur pour atteindre une dose de charge cible de denufosol d'environ 25-52 mg de denufosol par schéma posologique, nébulisation de la solution par passage à travers les trous d'un dispositif à mailles vibrant équipé d'une membrane oscillante dans le nébuliseur, et délivrance d'une dose respiratoire inhalée de 20-33 mg aux poumons du patient par inhalation dans les 3-9 minutes.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)